Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Joseph Turgeon as Senior Vice President Sales & Commercial Operations. Mr. Turgeon will be responsible for the commercialization and sales of all Spectrum products; currently, Spectrum markets FUSILEV
(levoleucovorin) for Injection; FOLOTYN
(pralatrexate injection); and ZEVALIN
(ibritumomab tiuxetan) Injection for intravenous use. Mr. Turgeon brings over 25 years of pharma sales experience, including various executive leadership roles at Amgen. He will report to Ken Keller, Executive Vice President and Chief Operating Officer.
“With three anticancer drugs on the market now bringing nearly $300 million in pro forma revenue and nearly ten drugs in clinical development, we are committed to strong growth in the next five years,” said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. ”The addition of Mr. Turgeon following appointment of Mr. Keller earlier this year is part of a planned strategy for expedited growth of Spectrum Pharmaceuticals.”
“Having worked with Joe for over twenty years at Amgen, it is my honor to warmly welcome Mr. Turgeon to Spectrum. His impressive sales record at Amgen will be a welcome addition as Spectrum continues expanding its commercial presence on the global market,” stated Ken Keller, Executive Vice President, Chief Operating Officer of Spectrum Pharmaceuticals, Inc. “Joe’s leadership and strategic skills will be broadly beneficial to Spectrum as we pursue our aggressive international growth plans.”
“I am excited to head Spectrum’s sales and commercial operations, especially in light of the recent Allos acquisition, which I believe represents a strong opportunity for expanding sales. I look forward to working with the team in this capacity and building on Spectrum's growth momentum,” stated Mr. Turgeon.